SA
Therapeutic Areas
Protalix BioTherapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Elelyso® (taliglucerase alfa) | Gaucher disease (Type 1) | Approved/Commercial |
| Pegunigalsidase alfa (PRX-102) | Fabry disease | Phase 3 |
| PRX-115 | Severe Hyperuricemia and Gout | Preclinical |
| PRX-119 | Hematological Disorders | Preclinical |
| Anti-TNFα (PRX-106) | Inflammatory Bowel Disease (e.g., Ulcerative Colitis) | Phase 1/2 |
| Alidornase alfa (PRX-110) | Cystic Fibrosis | Phase 1 |
Leadership Team at Protalix BioTherapeutics
DB
Dror Bashan
Chairman of the Board and Acting Chief Executive Officer
ER
Eyal Rubin
Senior Vice President, Chief Financial Officer and Treasurer
YS
Yoseph Shaaltiel
Executive Vice President, Research and Development
EB
Einat Brill Almon
Senior Vice President, Product Development
YN
Yaron Naos
Senior Vice President, Operations